Overview

Venlafaxine Augmentation in Treatment Resistant Depression

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.
Phase:
Phase 4
Details
Lead Sponsor:
Max-Planck-Institute of Psychiatry
Treatments:
Quetiapine Fumarate
Venlafaxine Hydrochloride